Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEKAMLO is an oral tablet small-molecule combination product approved by Novartis in 2010. The specific mechanism of action and indications are not publicly detailed in available data, limiting characterization of its therapeutic scope. It represents a formulation-based innovation in the small-molecule space.
Peak3.6 years to LOE
Peak lifecycle status suggests stable commercial operations, but high competitive pressure (8/10) indicates defensive positioning; brand team focus likely on retention and cost management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on TEKAMLO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.